Thomas Joe, Ohtsuka Masahisa, Pichler Martin, Ling Hui
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Division of Oncology, Medical University of Graz, 8010 Graz, Austria.
Int J Mol Sci. 2015 Nov 25;16(12):28063-76. doi: 10.3390/ijms161226080.
Colorectal cancer is one of the most common cancer diagnoses and causes of mortality worldwide. MicroRNAs are a class of small, non-coding regulatory RNAs that have shown strong associations with colorectal cancer. Through the repression of target messenger RNAs, microRNAs modulate many cellular pathways, such as those involved in cell proliferation, apoptosis, and differentiation. The utilization of microRNAs has shown significant promise in the diagnosis and prognosis of colorectal cancer, owing to their unique expression profile associations with cancer types and malignancies. Moreover, microRNA therapeutics with mimics or antagonists show great promise in preclinical studies, which encourages further development of their clinical use for colorectal cancer patients. The unique ability of microRNAs to affect multiple downstream pathways represents a novel approach for cancer therapy. Although still early in its development, we believe that microRNAs can be used in the near future as biomarkers and therapeutic targets for colorectal cancer.
结直肠癌是全球最常见的癌症诊断类型和死亡原因之一。微小RNA是一类小型非编码调节RNA,已显示出与结直肠癌有密切关联。通过抑制靶信使RNA,微小RNA调节许多细胞途径,如参与细胞增殖、凋亡和分化的途径。由于微小RNA与癌症类型和恶性肿瘤具有独特的表达谱关联,其在结直肠癌的诊断和预后方面显示出巨大潜力。此外,使用模拟物或拮抗剂的微小RNA疗法在临床前研究中显示出很大前景,这鼓励进一步开发其在结直肠癌患者临床治疗中的应用。微小RNA影响多个下游途径的独特能力代表了一种新型癌症治疗方法。尽管仍处于早期开发阶段,但我们相信微小RNA在不久的将来可作为结直肠癌的生物标志物和治疗靶点。